Parithera Company
Precision oncology includes new ways of treating cancer such as targeted therapies and immunotherapies. These approaches are more specific and effective than current treatments. In the near future, they will considerably reduce worldwide cancer burden.
As of today, only a fraction of the 18 million yearly diagnosed patients benefit from precision oncology. To increase the number of beneficiaries, new diagnostic tools are needed to match the specific needs of precision oncology to define patients' eligibility and monitor treatment response.
Founded Date:
2021-01-01
Employee Number:
1-10
Headquarters:
Lausanne, Vaud, Switzerland, Europe
Industry:
Biomarkers & Liquid Biopsy
Super Industry:
Diagnostics & Genomics
Investors:
Biop?le, DayOne accelerator, Federal Polytechnic School of Lausanne
Ipo Status:
private
City:
Lausanne
Region:
Vaud
Country:
Switzerland
Founders:
Antoine Herzog, Weida Chen